HDAC6/HSP90 Dual Inhibitor Design and SAR Overview

A 986.6 KB collection of TIF images, likely containing figures and diagrams, summarizing the rationale for dual-target cancer therapies. The review, authored by Sandipan Dash and last updated in May 2026, explores the design of small molecules inhibiting both HDAC6 and HSP90 proteins. It analyzes various chemotypes to elucidate structure-activity relationship principles for this synergistic anticancer strategy.

Use Cases

• Analyzing pharmacophore models for dual HDAC6/HSP90 inhibition based on described key structural elements.
• Comparing chemotype scaffolds, such as hybrid hydroxamates and fused heterocyclic systems, for drug design.
• Studying structure-activity relationship principles for optimizing linker length and cap group interactions.
• Reviewing the synergistic rationale for multi-targeted agents to overcome drug resistance in cancer.

Strengths

• File size is precisely 986.6 KB, indicating a defined and likely complete set of image files.
• The description provides a detailed scientific rationale and specific pharmacophoric elements for the drug class.
• License is clearly defined as CC-BY-4.0, permitting broad reuse with attribution.

Limitations

• Row count is unknown, which may limit suitability assessment for quantitative analysis.
• Column-level documentation is absent; the specific content and labeling of image data must be inferred after download.
• The dataset's scope is limited to a review overview, not a primary database of molecular structures or assay results.

Provenance

Source

figshare, authored by Sandipan Dash.

Collection Method

Likely compiled as a visual summary for a scientific review article.

Freshness

Last updated 2026-05-21 05:21:14; freshness should be verified.